Multikine is under clinical development by CEL-SCI and currently in Phase III for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase III drugs for Head And Neck Cancer Squamous Cell Carcinoma have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Multikine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Multikine overview

Multikine (Leukocyte Interleukin) is under development for the treatment of squamous cell carcinoma of the head and neck including oral cavity and cervical dysplasia in HIV/HPV co-infected women. The drug candidate is administered through the parenteral route as injection. The therapeutic candidate is a natural mixture of pro-inflammatory cytokines and chemokines (containing: IL-2, IL-1 beta, IFN-gamma, TNF-alpha and GM-CSF). It was also under development for the treatment of peri-anal warts (condyloma acuminata), chemotherapy effects due to head and neck or soft palate cancer, prostate cancer and radiation toxicity.

CEL-SCI overview

CEL-SCI is a biotechnology company that carries out the research and development of new immunotherapy products for the treatment of various cancer, autoimmune, and infectious diseases. Its core capabilities include drug discovery, research, development and manufacture of compound biological substances. CEL-SCI’s lead candidate, Multikine (leukocyte interleukin), is an investigational immunotherapy against cancer and human papilloma virus (HPV). The company is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 in hospitalized patients and vaccines, CEL-2000 and CEL-4000 for rheumatoid arthritis using Ligand Epitope Antigen Presentation System (LEAPS) technology platform. CEL-SCI is headquartered in Fairfax, Virginia, the US.

For a complete picture of Multikine’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.